HomeTrialNCT03604835
🔬NCT03604835RECRUITING

Mucopolysaccharidosis VII Disease Monitoring Program

Study Summary

The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment50 participants
Primary Completion
Lead SponsorUltragenyx Pharmaceutical Inc
Data Retrieved2026-04-11 04:25:35.045716+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.